eversyn

About:

Making high-value glycans mainstream

Top Investors: EXIST

Description:

eversyn is a spin-off of the Max Planck Institute Magdeburg, pioneers cell-free biosynthesis, advancing beyond precision fermentation. They design multi-enzyme pathways for the efficient production of activated sugars. This patented technology breakthrough underpins their unique commercial feasibility for many high-value glycans, notably complex human milk oligosaccharides and tailored therapeutic protein glycosylation.

Total Funding Amount:

1.1M EUR

Headquarters Location:

Magdeburg, Sachsen-Anhalt, Germany

Founded Date:

2024-01-16

Contact Email:

info(AT)eversyn.de

Founders:

Dr. Thomas Rexer

Number of Employees:

1-10

Last Funding Date:

2024-01-01

IPO Status:

Private

Industries: